^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
Published date:
07/11/2022
Excerpt:
PFS benefited to different degrees after first-line ICI-based treatment in each genetic classification....CHE/BEV prolonged mPFS of KRAS/STK11 co-mutation (p = 0.043), but decreased mPFS in G12A subtype (p = 0.026)...the clinical outcome of KRAS-mutant NSCLC patients benefits from a first-line ICI-based therapeutic regime to varying degrees.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.3390/jcm11144003
